Black Diamond Therapeutics, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Black Diamond reported Phase 2 results for silevertinib in 43 frontline non-classical EGFRm NSCLC patients (data cutoff April 11, 2026): 60% ORR, 86% CNS ORR in baseline brain metastases, 0 de novo brain metastases, 15.2-month median PFS, 91% DCR. Cash declined from $128.7M (Dec 2025) to $110.5M (June 2026); company expects funding into 2H 2028. Q2 2026 net loss was $9.9M vs. $10.6M in Q2 2025. FDA feedback on pivotal path expected Q4 2026.
Why this rating
Clinical efficacy data is compelling for lead asset; strong cash position (97% of market cap) extends runway. Material development milestone but clinical stage—FDA approval uncertain; significant relative to ~$114M company size.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.